This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evers, D. L. Articles by Drach, J. C. Search for Related Content PubMed PubMed Citation Articles by Evers, D. L. Articles by Drach, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2470-2476, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2470-2476.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Inhibition of Cyclin-Dependent Kinase 1 by Purines and Pyrrolo[2,3-d]Pyrimidines Does Not Correlate with Antiviral Activity

Department of Biologic and Materials Sciences, School of Dentistry,¹ Interdepartmental Graduate Program in Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109²

Received 16 October 2001/ Returned for modification 17 January 2002/ Accepted 18 April 2002

We have previously shown that a series of nonnucleoside pyrrolo[2,3-d]pyrimidines selectively inhibit the replication of herpes simplex virus type 1 (HSV-1) and human cytomegalovirus (HCMV). These compounds act at the immediate-early or early stage of HCMV replication and have antiviral properties somewhat similar to those of roscovitine and olomoucine, specific inhibitors of cyclin-dependent kinases (cdks). In the present study we examine the hypothesis that pyrrolo[2,3-d]pyrimidines exert their antiviral effects by inhibition of cellular cdks. Much higher concentrations of a panel of pyrrolo[2,3-d]pyrimidine nucleoside analogs with antiviral activity were required to inhibit recombinant cdk1/cyclin B compared to the submicromolar concentrations required to inhibit HCMV and HSV-1 replication. 4,6-Diamino-5-cyano-7-(2-phenylethyl)pyrrolo[2,3-d]pyrimidine (compound 1369) was the best inhibitor of cdk1 and cyclin B, with a 50% inhibitory concentration (IC₅₀; 14 µM) similar to that of roscovitine; it was competitive with respect to ATP (K_i = 14 µM). The potency of compound 1369 against cdk1 and cyclin B was similar to its cytotoxicity (IC₅₀s, 32 to 100 µM) but not its antiviral efficacy (IC₅₀s, 0.02 to 0.3 µM). Thus, our results indicated the null hypothesis. In contrast, roscovitine was only weakly active against HSV-1 (IC₅₀, 38 µM) and HCMV (IC₅₀, 40 µM). These values were similar to those derived by cytotoxicity and cell growth inhibition assays, thereby suggesting that roscovitine is not a selective antiviral. Therefore, we propose that inhibition of cdk1 and cyclin B is not responsible for selective antiviral activity and that pyrrolo[2,3-d]pyrimidines constitute novel pharmacophores which compete with ATP to inhibit cdk1 and cyclin B.

This article has been cited by other articles:

• Sanchez, V., McElroy, A. K., Yen, J., Tamrakar, S., Clark, C. L., Schwartz, R. A., Spector, D. H. (2004). Cyclin-Dependent Kinase Activity Is Required at Early Times for Accurate Processing and Accumulation of the Human Cytomegalovirus UL122-123 and UL37 Immediate-Early Transcripts and at Later Times for Virus Production. J. Virol. 78: 11219-11232 [Abstract] [Full Text]  
• Taylor, S. L., Kinchington, P. R., Brooks, A., Moffat, J. F. (2004). Roscovitine, a Cyclin-Dependent Kinase Inhibitor, Prevents Replication of Varicella-Zoster Virus. J. Virol. 78: 2853-2862 [Abstract] [Full Text]